ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that the first subjects have been dosed in a Phase I clinical study of XVR011, its llama-derived antibody for the treatment and prevention of COVID-19. Image Credit: ExeVir Bio The randomized, double-blinded, single-center, placebo-controlled Phase I clinical study will